To investigate the effect of mirabegron in the treatment of lower urinary tract symptoms caused by TURBt followed by BCG infusion of non-muscle-invasive bladder cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040823

Enrollment

Unknown

Registered

2020-12-11

Start date

2017-08-07

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower urinary tract syndromes

Interventions

mirabegron group:Oral mirabegron

Placebo group:oral placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18-80 with pathological diagnosis of high-risk NMIBC were eligible for inclusion.

Exclusion criteria

Exclusion criteria: Patients were excluded not only with bladder stones, glaucoma, obstruction of the bladder outlet, previous pelvic irradiation treatment, urinary tract infections, morbid obesity, chronic pain, chemical substance abuse, and severe renal or heart diseases, but also who were taking drugs beneficial to OAB.

Design outcomes

Primary

Measure	Time frame
OABSS;Pollakiuria;Micturition urgency;Hematuria;Urinary incontinence;Dysuria;	—

Secondary

Measure	Time frame
Nocturia;	—

Countries

China

Contacts

Public ContactJitao Wu

Yantai Yuhuangding Hospital

lhl897@126.com+86 18953568877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026